STEPS pack (System for Thalidomide Education and Prescribing Safety) - information about avoiding foetal exposure to thalidomide for prescribers and patients. Contains literature, surveys and consent forms.
Thalidomide is a drug with a chequered history. It is now marketed as a treatment for leprosy, HIV infections and some bone marrow cancers. Thalidomide was given to pregnant women in the late 1950s and early 1960s to ease morning sickness and aid sleep. The drug caused thousands of serious birth defects worldwide. Several hundred occurred in the UK. Babies were born with under-developed or missing limbs. The drug was withdrawn in 1962. Those affected by the drug have since fought for compensation.
The drug is now used under strictly controlled conditions. Celgene Corporation made and donated this example to the Science Museum’s collections. The company had Thalidomide approved for use by the American Food and Drug Administration in 1998. The corporation issued this pack that year to ensure doctors administered the drug correctly. It states all patients receiving Thalidomide must be registered with Celgene, undertake pregnancy tests before, during and after treatment, and use two forms of contraception at all times during treatment.
- Materia Medica & Pharmacology
- Object Number:
- information form
- visual and verbal communication
- Celgene Corporation
Cite this page
We encourage the use and reuse of our collection data.
Data in the title, made, maker and details fields are released under Creative Commons Zero
Descriptions and all other text content are licensed under a Creative Commons Attribution 4.0 licence
Download catalogue entry as json
View manifest in IIIF viewer
Download manifest IIIF
Our records are constantly being enhanced and improved, but please note that we cannot guarantee the accuracy of any information shown on this website.